Health Secretary Wes Streeting has come out swinging against major pharmaceutical companies, accusing them of greed and short-term thinking as negotiations over drug pricing between the UK government and industry stall.

In a sharp escalation of tensions, Streeting said he would “not allow British patients or taxpayers to be ripped off”, calling out drug companies for rejecting a government pricing offer that aimed to cap NHS spending on branded medicines.

A High-Stakes Deadlock

At the heart of the standoff is a long-standing voluntary agreement between the UK government and the pharmaceutical industry that limits NHS expenditure on branded drugs. The previous deal, VPAS (Voluntary Scheme for Branded Medicines Pricing and Access), expired earlier this year, and a new version has yet to be agreed.

The Department of Health had proposed a cap on drug price rises to ensure affordability for the NHS, but industry players – including several multinationals – walked away, claiming the offer was too restrictive and would hurt innovation and investment in the UK.

Streeting, however, is having none of it.

“It’s completely shortsighted for these companies to undermine their relationship with the UK by rejecting a fair deal,” he said. “They risk damaging public trust and their own reputations.”

“We’re Not a Blank Cheque”

The Health Secretary stressed that public funds must be spent wisely, especially as the NHS faces immense pressure post-COVID, with a backlog in operations, increasing demand for medicines, and the ongoing cost-of-living crisis.

“The NHS is not a blank cheque for pharmaceutical companies. We value innovation, but we also demand value for money,” Streeting added.

He argued that the UK has been one of the most cooperative and business-friendly environments for pharma companies globally, but those privileges cannot come without responsibility.

Industry Pushback

Pharmaceutical companies have responded by warning that restrictive pricing caps could limit patient access to the latest treatments, especially in areas like cancer, rare diseases, and advanced biologics.

They also argue that without fair returns on investment, companies will reduce clinical trials and research in the UK, potentially setting back the country’s ambitions to become a global life sciences leader.

One industry insider, speaking anonymously, said:

“We understand the need for financial discipline, but an overly aggressive cap is counterproductive. It sends a message that the UK is not serious about supporting innovation.”

Streeting’s Big Bet on Reform

Wes Streeting’s stance is consistent with his broader vision to reform the NHS, improve efficiency, and modernise how care is delivered. But it also signals a more combative approach to corporate accountability, especially when public money is at stake.

He’s betting that the public will support his hardline stance – especially amid widespread frustration over medicine shortages and NHS waiting times.

In recent weeks, Streeting has also called for:

• Faster rollout of cheaper generic alternatives
• Increased investment in domestic pharmaceutical production
• Transparent procurement processes for high-cost treatments

Will Pharma Blink?

The breakdown in talks has left both sides at a crossroads. Without a new deal, the risk is a disrupted supply of key medicines, escalating costs, and a chilling effect on new drug launches in the UK.

But Streeting says he’s ready for a tough fight.

“We want a deal – a fair deal. But we will not compromise on the principle that public money must deliver public value,” he said.
“If companies think they can bully us into bad terms, they’ve picked the wrong government.”

What’s Next?

Negotiations are reportedly still ongoing behind the scenes, but the tone has turned increasingly public and political. If no deal is reached soon, the government may unilaterally impose new pricing rules, risking legal battles and further pushback from the global pharmaceutical sector.

Meanwhile, patients and doctors are watching closely.
The outcome could shape the future availability of cutting-edge drugs in the NHS – and set a precedent for how the UK balances public health priorities with corporate partnerships.

---